pioneer 9 semaglutide Dose-response, efficacy, and safety of oral monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial Top line data for higher

An everything-but-the-kitchen-sink mapping study of GLP1- receptor agonists compared to other diabetes medications, where 175 health outcomes were assessed between the two groups, was published this year and it highlighted a number of slight risk increases with GLP-1 receptor agonists

And a lot of them aren't FDA approved.

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics

The study indicates that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of the lean mass loss typically associated with GLP-1 therapy, while increasing fat loss